{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T02:33:18Z","timestamp":1768789998738,"version":"3.49.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T00:00:00Z","timestamp":1689638400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T00:00:00Z","timestamp":1689638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the program of the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["(Grant No. 81873261)"],"award-info":[{"award-number":["(Grant No. 81873261)"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Gout is a common inflammatory arthritis caused by increased serum uric acid levels. Untreated or insufficiently treated gout can lead to deposition of monosodium urate crystals in joints, cartilage, and kidneys. Although Tongfengding capsules, a Chinese patent medicine, have long been used to treat gout, their effects and safety have not been reviewed systematically. This study evaluated its efficacy and safety for gout in adults.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Randomized controlled trials involving Tongfengding capsule for gout in adults were searched from PubMed, EMBASE, Cochrane Central Register of Controlled Trials, CBM, CNKI, and VIP databases, and analyzed using the Cochrane Handbook criteria. The primary outcome measures were the total effective rate. The secondary outcome measures including the blood uric acid (BUA), 24-h urinary total protein (24-h UTP), blood urea nitrogen (BUN), interleukin (IL)-6, IL-8, tumor necrosis factor-alpha (TNF-\u03b1) and adverse effects. The risk of bias was evaluated in all included studies. RevMan ver. 5.3.5 and GRADE profiler was used for data analysis and assessing the quality of evidence, respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Six studies (n\u2009=\u2009607 Chinese participants) were included. Tongfengding capsules plus conventional treatment significantly increased the total effective rate (RR 1.21, 95% CI 1.11\u20131.33), while reducing the BUA (MD \u2212\u200966.05\u00a0\u00b5mol\/L, 95% CI \u2212\u200981.26 to \u2212\u200950.84), 24-h UTP (MD \u2212\u20090.83\u00a0g\/24\u00a0h, 95% CI \u2212\u20090.96 to \u2212\u20090.70), BUN (MD \u2212\u20090.90\u00a0mmol\/L, 95% CI \u2212\u20091.60 to \u2212\u20090.20), IL-6 (MD \u2212\u20096.99\u00a0ng\/L, 95% CI \u2212\u200913.22 to \u2212\u20090.75), IL-8 (MD \u2212\u200912.17\u00a0ng\/L, 95% CI \u2212\u200918.07 to \u2212\u20096.27), TNF-\u03b1 (MD \u2212\u20098.50\u00a0ng\/L, 95% CI \u2212\u200915.50 to \u2212\u20091.51), and adverse effects (RR 0.21, 95% CI 0.04\u20130.95).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Tongfengding capsules plus conventional treatment is safe and beneficial for adults with gout compared with conventional treatment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s42358-023-00310-6","type":"journal-article","created":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T15:14:04Z","timestamp":1689693244000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Chinese patent medicine Tongfengding capsule for gout in adults: a systematic review of safety and effectiveness"],"prefix":"10.1186","volume":"63","author":[{"given":"Qiaoli","family":"Hua","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xusheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yujie","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kairong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ai","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1368-407X","authenticated-orcid":false,"given":"Qianchun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,18]]},"reference":[{"key":"310_CR1","doi-asserted-by":"publisher","first-page":"212581","DOI":"10.7573\/dic.212581","volume":"8","author":"F P\u00e9rez-Ruiz","year":"2019","unstructured":"P\u00e9rez-Ruiz F, Jansen T, Tausche AK, et al. Efficacy and safety of lesinurad for the treatment of hyperuricemia in gout. Drug in Context. 2019;8:212581. https:\/\/doi.org\/10.7573\/dic.212581.","journal-title":"Drug in Context"},{"issue":"11","key":"310_CR2","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.3390\/molecules24112138","volume":"24","author":"HE Lee","year":"2019","unstructured":"Lee HE, Yang G, Park YB, et al. Epigallocatechin-3-gallate prevents acute gout by suppressing NLRP3 inflammasome activation and mitochondrial DNA synthesis. Molecules. 2019;24(11):2138. https:\/\/doi.org\/10.3390\/molecules24112138.","journal-title":"Molecules"},{"issue":"3","key":"310_CR3","first-page":"1859","volume":"16","author":"X Liu","year":"2018","unstructured":"Liu X, Liu K, Sun Q, et al. Efficacy and safety of febuxostat for treating hyperuricemia in patients with chronic kidney disease and in renal transplant recipients: a systematic review and meta-analysis. Exp Ther Med. 2018;16(3):1859\u201365.","journal-title":"Exp Ther Med"},{"issue":"1","key":"310_CR4","doi-asserted-by":"publisher","first-page":"e85008","DOI":"10.1371\/journal.pone.0085008","volume":"9","author":"L Zhou","year":"2014","unstructured":"Zhou L, Liu L, Liu XY, et al. Systematic review and meta-analysis of the clinical efficacy and adverse effects of Chinese herbal decoction for the treatment of gout. PLOS ONE. 2014;9(1):e85008.","journal-title":"PLOS ONE"},{"key":"310_CR5","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1111\/j.1742-1241.2009.02263.x","volume":"64","author":"O Sinan Deveci","year":"2010","unstructured":"Sinan Deveci O, Kabakci G, Okutucu S, et al. The association between serum uric acid level and coronary artery disease. Int J Clin Pract. 2010;64:900\u20137.","journal-title":"Int J Clin Pract"},{"key":"310_CR6","unstructured":"Ye RG. Internal medicine Chinese people\u2019s medical publishing house. 2001. p. 877\u201384."},{"key":"310_CR7","first-page":"505","volume":"20","author":"Q Dang","year":"2006","unstructured":"Dang Q, Wang J, Zhang Y, et al. Study on the relationship between hyperuricemia andcardiovascular events in hypertension. J Pract Diagn Therapy. 2006;20:505\u20136.","journal-title":"J Pract Diagn Therapy"},{"key":"310_CR8","doi-asserted-by":"publisher","first-page":"e0170393","DOI":"10.1371\/journal.pone.0170393","volume":"12","author":"CW Tsai","year":"2017","unstructured":"Tsai CW, Lin SY, Kuo CC, et al. Serum uric acid and progression of kidney disease: a longitudinal analysis and mini-review. PLOS ONE. 2017;12:e0170393.","journal-title":"PLOS ONE"},{"key":"310_CR9","first-page":"2403","volume":"29","author":"E Arromdee","year":"2002","unstructured":"Arromdee E, Michet CJ, Crowson CS, et al. Epidemiology of gout: is the incidence rising? J Rheumatol. 2002;29:2403\u20136.","journal-title":"J Rheumatol"},{"key":"310_CR10","doi-asserted-by":"publisher","first-page":"3136","DOI":"10.1002\/art.30520","volume":"63","author":"Y Zhu","year":"2011","unstructured":"Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007\u20132008. Arthritis Rheum. 2011;63:3136\u201341.","journal-title":"Arthritis Rheum"},{"key":"310_CR11","first-page":"1759720X1984701","volume":"11","author":"MW Collins","year":"2019","unstructured":"Collins MW, Saag KG, Singh JA. Is there a role for cherries in the management of gout? Therapeutic Adv Chronic Dis. 2019;11:1759720X19847018.","journal-title":"Therapeutic Adv Chronic Dis"},{"key":"310_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/art.40807","author":"M Chen-Xu","year":"2019","unstructured":"Chen-Xu M, Yokose C, Rai SK, et al. Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: the National Health and nutrition examination survey, 2007\u20132016. Arthritis Rheumatol. 2019. https:\/\/doi.org\/10.1002\/art.40807.","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"310_CR13","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1136\/annrheumdis-2013-204463","volume":"74","author":"CF Kuo","year":"2015","unstructured":"Kuo CF, Grainge MJ, Mallen C, et al. Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Ann Rheum Dis. 2015;74(4):661\u20137.","journal-title":"Ann Rheum Dis"},{"key":"310_CR14","first-page":"5","volume":"45","author":"K Ting","year":"2015","unstructured":"Ting K, Hill C, Gill T, et al. Prevalence and associations of gout and hyperuricaemia: results from an Australian population-based study. Intern Med J. 2015;45:5.","journal-title":"Intern Med J"},{"key":"310_CR15","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/ar3199","volume":"12","author":"R Edward","year":"2010","unstructured":"Edward R, Doherty M. Epidemiology of gout. Arthritis Res Ther. 2010;12:223.","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"310_CR16","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s10067-013-2274-7","volume":"32","author":"XX Li","year":"2013","unstructured":"Li XX, Han M, Wang YY, et al. Chinese herbal medicine for gout: a systematic review of randomized clinical trials. Clin Rheumatol. 2013;32(7):943\u201359.","journal-title":"Clin Rheumatol"},{"key":"310_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.curtheres.2013.04.003","volume":"75","author":"A Wertheimer","year":"2013","unstructured":"Wertheimer A, Morlock R, Becker MA. A revised estimate of the burden of illness of gout. Curr Ther Res Clin Exp. 2013;75:1\u20134.","journal-title":"Curr Ther Res Clin Exp"},{"key":"310_CR18","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.2147\/DDDT.S97959","volume":"11","author":"G Jones","year":"2017","unstructured":"Jones G, Panova E, Day R. Guideline development for the management of gout: role of combination therapy with a focus on lesinurad. Drug Des Dev Ther. 2017;11:3077\u201381.","journal-title":"Drug Des Dev Ther"},{"issue":"1","key":"310_CR19","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1136\/annrheumdis-2012-202421","volume":"73","author":"F Perez-Ruiz","year":"2014","unstructured":"Perez-Ruiz F, Mart\u00ednez-Indart L, Carmona L, et al. Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout. Ann Rheum Dis. 2014;73(1):177\u201382.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"310_CR20","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.rdc.2014.01.003","volume":"40","author":"F Perez-Ruiz","year":"2014","unstructured":"Perez-Ruiz F, Castillo E, Chinchilla SP, et al. Clinical manifestations and diagnosis of gout. Rheum Dis Clin N Am. 2014;40(2):193\u2013206.","journal-title":"Rheum Dis Clin N Am"},{"key":"310_CR21","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1136\/ard.2006.055269","volume":"65","author":"W Zhang","year":"2006","unstructured":"Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis. 2006;65:1312\u201324.","journal-title":"Ann Rheum Dis"},{"key":"310_CR22","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1111\/1756-185X.12557","volume":"18","author":"SW Graf","year":"2015","unstructured":"Graf SW, Whittle SL, Wechalekar MD, et al. Australian and New Zealand recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion in the 3e Initiative. Int J Rheum Dis. 2015;18:341\u201351.","journal-title":"Int J Rheum Dis"},{"key":"310_CR23","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","volume":"76","author":"P Richette","year":"2017","unstructured":"Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76:29\u201342.","journal-title":"Ann Rheum Dis"},{"key":"310_CR24","doi-asserted-by":"publisher","first-page":"58","DOI":"10.7326\/M16-0570","volume":"166","author":"A Qaseem","year":"2017","unstructured":"Qaseem A, Harris RP, Forciea MA. Management of acute and recurrent gout: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2017;166:58\u201368.","journal-title":"Ann Intern Med"},{"key":"310_CR25","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1053\/gast.2000.9561","volume":"119","author":"CJ Hawkey","year":"2000","unstructured":"Hawkey CJ. Nonsteroidal anti-inflammatory drug gastropathy. Gastroenterology. 2000;119:521\u201335.","journal-title":"Gastroenterology"},{"key":"310_CR26","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S0140-6736(05)17864-7","volume":"65","author":"DJ Graham","year":"2005","unstructured":"Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet. 2005;65:475\u201381.","journal-title":"Lancet"},{"key":"310_CR27","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1056\/NEJMcp1001124","volume":"364","author":"T Neogi","year":"2011","unstructured":"Neogi T. Clinical practice. Gout. N Engl J Med. 2011;364:443\u201352.","journal-title":"N Engl J Med"},{"key":"310_CR28","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1056\/NEJMcp030733","volume":"349","author":"RA Terkeltaub","year":"2003","unstructured":"Terkeltaub RA. Clinical practice. Gout. N Engl J Med. 2003;349:1647\u201355.","journal-title":"N Engl J Med"},{"key":"310_CR29","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S0140-6736(09)60883-7","volume":"375","author":"P Richette","year":"2010","unstructured":"Richette P, Bardin T. Gout. Lancet. 2010;375:318\u201328.","journal-title":"Lancet"},{"key":"310_CR30","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1002\/art.20102","volume":"50","author":"TR Mikuls","year":"2004","unstructured":"Mikuls TR, MacLean CH, Olivieri J, et al. Quality of care indicators for gout management. Arthritis Rheum. 2004;50:937\u201343.","journal-title":"Arthritis Rheum"},{"key":"310_CR31","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/j.1742-1241.2009.02188.x","volume":"64","author":"JF Baker","year":"2010","unstructured":"Baker JF, Schumacher HR. Update on gout and hyperuricemia. Int J Clin Pract. 2010;64:371\u20137.","journal-title":"Int J Clin Pract"},{"key":"310_CR32","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1097\/01.rhu.0000147049.12220.32","volume":"10","author":"AA Riedel","year":"2004","unstructured":"Riedel AA, Nelson M, Wallace K, et al. Prevalence of comorbid conditions and prescription medication use among patients with gout and hyperuricemia in a managed care setting. JCR-J Clin Rheumatol. 2004;10:308\u201314.","journal-title":"JCR-J Clin Rheumatol"},{"key":"310_CR33","first-page":"180","volume":"7","author":"T Li","year":"2007","unstructured":"Li T, Liu X, Zhang M, et al. Assessment of systematic reviews and meta-analyses on traditional chinese medicine published in Chinese journals. Chin J Evid Based Med. 2007;7:180\u20138.","journal-title":"Chin J Evid Based Med"},{"key":"310_CR34","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1037\/1082-989X.11.2.193","volume":"11","author":"TB Huedo-Medina","year":"2006","unstructured":"Huedo-Medina TB, S\u00e1nchez-Meca J, Mar\u00edn-Mart\u00ednez F, et al. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods. 2006;11:193\u2013206.","journal-title":"Psychol Methods"},{"key":"310_CR35","doi-asserted-by":"crossref","unstructured":"Multidisciplinary Expert Task Force on Hyperuricemia and Related Diseases. Chinese multidisciplinary expert consensus on the diagnosis and treatment of hyperuricemia and related diseases. Chin Med J 2017; 130:2473\u201388.","DOI":"10.4103\/0366-6999.216416"},{"key":"310_CR36","unstructured":"Higgins JP, Green S (editors). Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration 2011. Available from https:\/\/www.cochrane-handbook.org"},{"key":"310_CR37","unstructured":"GRADEpro GDT: GRADEpro Guideline development tool [software]. McMaster University and Evidence Prime, 2022. Available from https:\/\/www.gradepro.org\/."},{"key":"310_CR38","unstructured":"Sch\u00fcnemann H, Bro\u017cek J, Guyatt G, Oxman A, editors. GRADE handbook for grading quality of evidence and strength of recommendations. Updated October 2013. The GRADE Working Group, 2013. Available from https:\/\/www.guidelinedevelopment.org\/handbook."},{"issue":"7174","key":"310_CR39","first-page":"227","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analysis. BMJ. 2003;327(7174):227\u201360.","journal-title":"BMJ"},{"issue":"21","key":"310_CR40","first-page":"2551","volume":"22","author":"L Tang","year":"2016","unstructured":"Tang L. Effect of allopurinol combined with Tongfengding capsule on inflammatory factors, hepatorenal functions, and related indicators in gouty patients. J Hainan Med Univ. 2016;22(21):2551\u20134.","journal-title":"J Hainan Med Univ"},{"issue":"10","key":"310_CR41","first-page":"1060","volume":"43","author":"Y Gao","year":"2015","unstructured":"Gao Y, Zhang ZR, Tang ZH, Lu J, Su Y. Clinical observation of Benzbromarone combined with Tongfengding capsules in treatment of gouty arthritis. Clin J Med Off. 2015;43(10):1060\u20132.","journal-title":"Clin J Med Off"},{"issue":"11","key":"310_CR42","first-page":"39","volume":"27","author":"S Chi","year":"2013","unstructured":"Chi S, Li K. Tongfengding capsule treat acute gouty arthritis randomized controlled study. J Pract Tradition Chin Internal Med. 2013;27(11):39\u201340.","journal-title":"J Pract Tradition Chin Internal Med"},{"issue":"7","key":"310_CR43","first-page":"737","volume":"26","author":"Y Tang","year":"2017","unstructured":"Tang Y. Effect of febuxostat combined with Tongfengding capsule on inflammatory factors in patients with hyperuricemia. Mod J Integr Tradition Chin West Med. 2017;26(7):737\u20139.","journal-title":"Mod J Integr Tradition Chin West Med"},{"issue":"5","key":"310_CR44","first-page":"38","volume":"6","author":"J Ao","year":"2019","unstructured":"Ao J. Observation on the curative effect of Tongfengding capsule in the treatment of senile gouty arthritis in the elderly. J Clin Med Lit. 2019;6(5):38\u20139.","journal-title":"J Clin Med Lit"},{"issue":"8","key":"310_CR45","first-page":"83","volume":"37","author":"LJ Wang","year":"2017","unstructured":"Wang LJ, Xiang Y, Yang QF, Sun QJ. Effects of Tongfengding capsule combined with diclofenac sodium on blood uric acid level and joint swelling and pain score in gout patients. Chin J Biochem Pharm. 2017;37(8):83\u20134.","journal-title":"Chin J Biochem Pharm"}],"container-title":["Advances in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-023-00310-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42358-023-00310-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-023-00310-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T15:19:26Z","timestamp":1689693566000},"score":1,"resource":{"primary":{"URL":"https:\/\/advancesinrheumatology.biomedcentral.com\/articles\/10.1186\/s42358-023-00310-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,18]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["310"],"URL":"https:\/\/doi.org\/10.1186\/s42358-023-00310-6","relation":{},"ISSN":["2523-3106"],"issn-type":[{"value":"2523-3106","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,18]]},"assertion":[{"value":"1 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All analyses were based on previous published studies,thus no ethical approval and patient consent are required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was obtained.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"32"}}